| Date:May 11,2023                                                                               |                 |
|------------------------------------------------------------------------------------------------|-----------------|
| Your Name:Junjie Chen                                                                          |                 |
| Manuscript Title: <u>Epithelial-mesenchymal transition is associated with OPN-induced EGFR</u> | -TKI resistance |
| in EGFR mutant non-small cell lung cancer                                                      |                 |
| Manuscript number (if known):                                                                  |                 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                            | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
|   |                                                                                            | Time frame: Since the initial                                                                            | planning of the work                                                                      |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials, | the Natural Science<br>Foundation of Zhejiang<br>Province                                                | LQ20H010002 to Junjie Chen                                                                |
|   | medical writing, article                                                                   | the Basic Scientific                                                                                     | Y20190522 to Junjie Chen                                                                  |
|   | processing charges, etc.)                                                                  | Research Program of                                                                                      |                                                                                           |
|   | No time limit for this item.                                                               | Wenzhou                                                                                                  |                                                                                           |
|   |                                                                                            | the Basic Scientific                                                                                     | Y20220341 to Junjie Chen                                                                  |
|   |                                                                                            | Research Program of                                                                                      |                                                                                           |
|   |                                                                                            | Wenzhou                                                                                                  |                                                                                           |
|   |                                                                                            |                                                                                                          |                                                                                           |
|   |                                                                                            | Time frame: past                                                                                         | 36 months                                                                                 |
| 2 | Grants or contracts from                                                                   | None                                                                                                     |                                                                                           |
|   | any entity (if not indicated                                                               |                                                                                                          |                                                                                           |
|   | in item #1 above).                                                                         |                                                                                                          |                                                                                           |
| 3 | Royalties or licenses                                                                      | None                                                                                                     |                                                                                           |
|   |                                                                                            |                                                                                                          |                                                                                           |
|   |                                                                                            |                                                                                                          |                                                                                           |

| 4        | Consulting fees                                       | None |  |
|----------|-------------------------------------------------------|------|--|
|          |                                                       |      |  |
| -        |                                                       | N    |  |
| 5        | Payment or honoraria for lectures, presentations,     | None |  |
|          | speakers bureaus,                                     |      |  |
|          | manuscript writing or                                 |      |  |
|          | educational events                                    |      |  |
| 6        | Payment for expert                                    | None |  |
|          | testimony                                             |      |  |
| 7        | Support for attending                                 | None |  |
| <i>'</i> | meetings and/or travel                                |      |  |
|          | <b>U</b>                                              |      |  |
|          |                                                       |      |  |
| 8        | Patents planned, issued or                            | None |  |
|          | pending                                               |      |  |
| 0        | Deuticiantica en e Dete                               | News |  |
| 9        | Participation on a Data<br>Safety Monitoring Board or | None |  |
|          | Advisory Board                                        |      |  |
| 10       | Leadership or fiduciary role                          | None |  |
|          | in other board, society,                              |      |  |
|          | committee or advocacy group, paid or unpaid           |      |  |
| 11       | Stock or stock options                                | None |  |
|          |                                                       |      |  |
|          |                                                       |      |  |
| 12       | Receipt of equipment,                                 | None |  |
|          | materials, drugs, medical<br>writing, gifts or other  |      |  |
|          | services                                              |      |  |
| 13       | Other financial or non-                               | None |  |
|          | financial interests                                   |      |  |
|          |                                                       |      |  |

*The author reports funding support from the Natural Science Foundation of Zhejiang Province (No. LQ20H010002), the Basic Scientific Research Program of Wenzhou (Nos. Y20190522 and Y20220341).* 

Please place an "X" next to the following statement to indicate your agreement:

| Date: May 11,2023                                                                                         |
|-----------------------------------------------------------------------------------------------------------|
| Your Name:Lin Shi                                                                                         |
| Manuscript Title: Epithelial-mesenchymal transition is associated with OPN-induced EGFR-TKI resistance in |
| EGFR mutant non-small cell lung cancer                                                                    |
| Manuscript number (if known):                                                                             |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                                            | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)                                                         | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                            | Time frame: Since the initial                                                                                                                                    | planning of the work                                                                      |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | the Key Laboratory of<br>Interventional<br>Pulmonology of Zhejiang<br>Province<br>the National Nature<br>Science Foundation of<br>China<br>the Outstanding Youth | 2019E10014 to Lin Shi<br>81800034 to Lin Shi<br>2021ZSYQ25 to Lin Shi                     |
|   |                                                                                                                                                                                            | Foundation of Zhongshan                                                                                                                                          |                                                                                           |
|   |                                                                                                                                                                                            | Hospital                                                                                                                                                         | 26 months                                                                                 |
| 2 | Crants or contracts from                                                                                                                                                                   | Time frame: past                                                                                                                                                 | 36 months                                                                                 |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).                                                                                                             | None                                                                                                                                                             |                                                                                           |
| 3 | Royalties or licenses                                                                                                                                                                      | None                                                                                                                                                             |                                                                                           |
|   |                                                                                                                                                                                            |                                                                                                                                                                  |                                                                                           |

| 4  | Consulting fees                                       | None |  |
|----|-------------------------------------------------------|------|--|
|    |                                                       |      |  |
| -  |                                                       | N    |  |
| 5  | Payment or honoraria for lectures, presentations,     | None |  |
|    | speakers bureaus,                                     |      |  |
|    | manuscript writing or                                 |      |  |
|    | educational events                                    |      |  |
| 6  | Payment for expert                                    | None |  |
|    | testimony                                             |      |  |
| 7  | Support for attending                                 | None |  |
| '  | meetings and/or travel                                |      |  |
|    | 5 ,                                                   |      |  |
|    |                                                       |      |  |
| 8  | Patents planned, issued or                            | None |  |
|    | pending                                               |      |  |
| 9  | Darticipation on a Data                               | Nana |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or | None |  |
|    | Advisory Board                                        |      |  |
| 10 | Leadership or fiduciary role                          | None |  |
|    | in other board, society,                              |      |  |
|    | committee or advocacy<br>group, paid or unpaid        |      |  |
| 11 | Stock or stock options                                | None |  |
|    |                                                       |      |  |
| 42 |                                                       |      |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical    | None |  |
|    | writing, gifts or other                               |      |  |
|    | services                                              |      |  |
| 13 | Other financial or non-                               | None |  |
|    | financial interests                                   |      |  |
|    |                                                       |      |  |

The author reports funding support from the Key Laboratory of Interventional Pulmonology of Zhejiang Province (No. 2019E10014), the National Nature Science Foundation of China (No. 81800034), the Outstanding Youth Foundation of Zhongshan Hospital (No. 2021ZSYQ25).

#### Please place an "X" next to the following statement to indicate your agreement:

| Date:May 11,2023                                                                                      |
|-------------------------------------------------------------------------------------------------------|
| Your Name: Yao Qian                                                                                   |
| Manuscript Title: Epithelial-mesenchymal transition is associated with OPN-induced EGFR-TKI resistanc |
| in EGFR mutant non-small cell lung cancer                                                             |
| Manuscript number (if known):                                                                         |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
|   |                               | Time frame: Since the initial                                                                            | planning of the work                                                                      |
| 1 | All support for the present   | None                                                                                                     |                                                                                           |
|   | manuscript (e.g., funding,    |                                                                                                          |                                                                                           |
|   | provision of study materials, |                                                                                                          |                                                                                           |
|   | medical writing, article      |                                                                                                          |                                                                                           |
|   | processing charges, etc.)     |                                                                                                          |                                                                                           |
|   | No time limit for this item.  |                                                                                                          |                                                                                           |
|   |                               |                                                                                                          |                                                                                           |
|   |                               |                                                                                                          |                                                                                           |
|   |                               | Time frame: past                                                                                         | 36 months                                                                                 |
| 2 | Grants or contracts from      | None                                                                                                     |                                                                                           |
|   | any entity (if not indicated  |                                                                                                          |                                                                                           |
|   | in item #1 above).            |                                                                                                          |                                                                                           |
| 3 | Royalties or licenses         | None                                                                                                     |                                                                                           |
|   |                               |                                                                                                          |                                                                                           |
|   |                               |                                                                                                          |                                                                                           |
| 4 | Consulting fees               | None                                                                                                     |                                                                                           |
|   |                               |                                                                                                          |                                                                                           |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | None |  |
|----|--------------------------------------------------------------------------------------------------------------------------|------|--|
| 6  | Payment for expert testimony                                                                                             | None |  |
| 7  | Support for attending meetings and/or travel                                                                             | None |  |
| 8  | Patents planned, issued or pending                                                                                       | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                                  | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | None |  |
| 11 | Stock or stock options                                                                                                   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | None |  |
| 13 | Other financial or non-<br>financial interests                                                                           | None |  |

None

Please place an "X" next to the following statement to indicate your agreement:

| Date: May 11,2023                                                                                      |
|--------------------------------------------------------------------------------------------------------|
| Your Name:Yi Jin                                                                                       |
| Manuscript Title: Epithelial-mesenchymal transition is associated with OPN-induced EGFR-TKI resistance |
| in EGFR mutant non-small cell lung cancer                                                              |
| Manuscript number (if known):                                                                          |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                            | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
|   |                                                                                            | Time frame: Since the initial                                                                            |                                                                                           |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials, | the Basic Scientific<br>Research Program of<br>Wenzhou                                                   | Y20190207 to Yi Jin                                                                       |
|   | medical writing, article                                                                   |                                                                                                          |                                                                                           |
|   | processing charges, etc.)                                                                  |                                                                                                          |                                                                                           |
|   | No time limit for this item.                                                               |                                                                                                          |                                                                                           |
|   |                                                                                            |                                                                                                          |                                                                                           |
|   |                                                                                            |                                                                                                          |                                                                                           |
|   |                                                                                            | Time frame: past                                                                                         | 36 months                                                                                 |
| 2 | Grants or contracts from                                                                   | None                                                                                                     |                                                                                           |
|   | any entity (if not indicated                                                               |                                                                                                          |                                                                                           |
|   | in item #1 above).                                                                         |                                                                                                          |                                                                                           |
| 3 | Royalties or licenses                                                                      | None                                                                                                     |                                                                                           |
|   |                                                                                            |                                                                                                          |                                                                                           |
|   |                                                                                            |                                                                                                          |                                                                                           |
| 4 | Consulting fees                                                                            | None                                                                                                     |                                                                                           |
|   |                                                                                            |                                                                                                          |                                                                                           |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | None |  |
|----|--------------------------------------------------------------------------------------------------------------------------|------|--|
| 6  | Payment for expert<br>testimony                                                                                          | None |  |
| 7  | Support for attending meetings and/or travel                                                                             | None |  |
| 8  | Patents planned, issued or pending                                                                                       | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                                  | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | None |  |
| 11 | Stock or stock options                                                                                                   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | None |  |
| 13 | Other financial or non-<br>financial interests                                                                           | None |  |

*The author reports funding support from the Basic Scientific Research Program of Wenzhou* (*No.Y20190207*)

Please place an "X" next to the following statement to indicate your agreement:

| Date: May 11,2023                 |                                                                            |           |
|-----------------------------------|----------------------------------------------------------------------------|-----------|
| Your Name: <u>Nian Dong</u>       |                                                                            |           |
| Manuscript Title: <u>Epitheli</u> | al-mesenchymal transition is associated with OPN-induced EGFR-TKI resistan | <u>ce</u> |
| in EGFR mutant non-sn             | all cell lung cancer                                                       |           |
| Manuscript number (if kno         | vn):                                                                       |           |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
|   |                               | Time frame: Since the initial                                                                            | planning of the work                                                                      |
| 1 | All support for the present   | None                                                                                                     |                                                                                           |
|   | manuscript (e.g., funding,    |                                                                                                          |                                                                                           |
|   | provision of study materials, |                                                                                                          |                                                                                           |
|   | medical writing, article      |                                                                                                          |                                                                                           |
|   | processing charges, etc.)     |                                                                                                          |                                                                                           |
|   | No time limit for this item.  |                                                                                                          |                                                                                           |
|   |                               |                                                                                                          |                                                                                           |
|   |                               |                                                                                                          |                                                                                           |
|   |                               | Time frame: past                                                                                         | 36 months                                                                                 |
| 2 | Grants or contracts from      | None                                                                                                     |                                                                                           |
|   | any entity (if not indicated  |                                                                                                          |                                                                                           |
|   | in item #1 above).            |                                                                                                          |                                                                                           |
| 3 | Royalties or licenses         | None                                                                                                     |                                                                                           |
|   |                               |                                                                                                          |                                                                                           |
|   |                               |                                                                                                          |                                                                                           |
| 4 | Consulting fees               | None                                                                                                     |                                                                                           |
|   |                               |                                                                                                          |                                                                                           |

| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, | None |  |
|----|---------------------------------------------------------------------|------|--|
|    | manuscript writing or<br>educational events                         |      |  |
| 6  | Payment for expert testimony                                        | None |  |
| 7  | Support for attending meetings and/or travel                        | None |  |
|    |                                                                     |      |  |
|    |                                                                     |      |  |
| 8  | Patents planned, issued or pending                                  | None |  |
| 9  | Participation on a Data                                             | None |  |
| 5  | Safety Monitoring Board or                                          |      |  |
|    | Advisory Board                                                      |      |  |
| 10 | Leadership or fiduciary role                                        | None |  |
|    | in other board, society,                                            |      |  |
|    | committee or advocacy group, paid or unpaid                         |      |  |
| 11 | Stock or stock options                                              | None |  |
|    |                                                                     |      |  |
| 12 | Dessint of any invest                                               | News |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical                  | None |  |
|    | writing, gifts or other                                             |      |  |
| 13 | services<br>Other financial or non-                                 | Nono |  |
| 13 | financial interests                                                 | None |  |
|    |                                                                     |      |  |

None

Please place an "X" next to the following statement to indicate your agreement:

| Date: May 11,2023                                                                                 |        |
|---------------------------------------------------------------------------------------------------|--------|
| Your Name: Chengshui Chen                                                                         |        |
| Manuscript Title: Epithelial-mesenchymal transition is associated with OPN-induced EGFR-TKI resis | stance |
| in EGFR mutant non-small cell lung cancer                                                         |        |
| Manuscript number (if known):                                                                     |        |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                                            | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                            | Time frame: Since the initial                                                                            | planning of the work                                                                      |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None                                                                                                     |                                                                                           |
|   |                                                                                                                                                                                            | Time frame: past                                                                                         | 36 months                                                                                 |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).                                                                                                             | None                                                                                                     |                                                                                           |
| 3 | Royalties or licenses                                                                                                                                                                      | None                                                                                                     |                                                                                           |
| 4 | Consulting fees                                                                                                                                                                            | None                                                                                                     |                                                                                           |

| 5  | Payment or honoraria for lectures, presentations,                | None |  |
|----|------------------------------------------------------------------|------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events |      |  |
| 6  | Payment for expert testimony                                     | None |  |
| 7  | Support for attending meetings and/or travel                     | None |  |
|    |                                                                  |      |  |
|    |                                                                  |      |  |
| 8  | Patents planned, issued or pending                               | None |  |
| 9  | Participation on a Data                                          | None |  |
| -  | Safety Monitoring Board or                                       |      |  |
|    | Advisory Board                                                   |      |  |
| 10 | Leadership or fiduciary role                                     | None |  |
|    | in other board, society,                                         |      |  |
|    | committee or advocacy group, paid or unpaid                      |      |  |
| 11 | Stock or stock options                                           | None |  |
|    |                                                                  |      |  |
|    |                                                                  |      |  |
| 12 | Receipt of equipment,                                            | None |  |
|    | materials, drugs, medical                                        |      |  |
|    | writing, gifts or other<br>services                              |      |  |
| 13 | Other financial or non-                                          | None |  |
|    | financial interests                                              |      |  |
|    |                                                                  |      |  |

None

Please place an "X" next to the following statement to indicate your agreement:

| Date: May 11,2023                                                                                      |
|--------------------------------------------------------------------------------------------------------|
| Your Name: Beibei Wang                                                                                 |
| Manuscript Title: Epithelial-mesenchymal transition is associated with OPN-induced EGFR-TKI resistance |
| in EGFR mutant non-small cell lung cancer                                                              |
| Manuscript number (if known):                                                                          |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                            | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
|   |                                                                                            | Time frame: Since the initial                                                                            | planning of the work                                                                      |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials, | the Health science and<br>Technology Project of<br>Zhejiang Province                                     | 2022RC047 to Beibei Wang                                                                  |
|   | medical writing, article<br>processing charges, etc.)<br>No time limit for this item.      | the Basic Scientific<br>Research Program of<br>Wenzhou                                                   | Y20220038 to Beibei Wang                                                                  |
|   |                                                                                            |                                                                                                          |                                                                                           |
|   |                                                                                            | Time frame: past                                                                                         | 36 months                                                                                 |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).             | None                                                                                                     |                                                                                           |
| 3 | Royalties or licenses                                                                      | None                                                                                                     |                                                                                           |
| 4 | Consulting fees                                                                            | None                                                                                                     |                                                                                           |

| 5  | Payment or honoraria for                        | None |  |
|----|-------------------------------------------------|------|--|
|    | lectures, presentations,                        |      |  |
|    | speakers bureaus,                               |      |  |
|    | manuscript writing or                           |      |  |
| 6  | educational events                              | Nere |  |
| 6  | Payment for expert                              | None |  |
|    | testimony                                       |      |  |
| 7  | Support for attanding                           | None |  |
| /  | Support for attending<br>meetings and/or travel |      |  |
|    | meetings and/or traver                          |      |  |
|    |                                                 |      |  |
|    |                                                 |      |  |
| 8  | Patents planned, issued or                      | None |  |
| Ŭ  | pending                                         |      |  |
|    | B                                               |      |  |
| 9  | Participation on a Data                         | None |  |
|    | Safety Monitoring Board or                      |      |  |
|    | Advisory Board                                  |      |  |
| 10 | Leadership or fiduciary role                    | None |  |
|    | in other board, society,                        |      |  |
|    | committee or advocacy                           |      |  |
|    | group, paid or unpaid                           |      |  |
| 11 | Stock or stock options                          | None |  |
|    |                                                 |      |  |
|    |                                                 |      |  |
| 12 | Receipt of equipment,                           | None |  |
|    | materials, drugs, medical                       |      |  |
|    | writing, gifts or other services                |      |  |
| 13 | Other financial or non-                         | None |  |
| 12 | financial interests                             |      |  |
|    |                                                 |      |  |
|    |                                                 |      |  |

The author reports funding support from the Health science and Technology Project of Zhejiang Province (No. 2022RC047) and the Basic Scientific Research Program of Wenzhou (No. Y20220038).

Please place an "X" next to the following statement to indicate your agreement: